American Cancer Society endorses HPV vaccine recommendations from CDC

July 19, 2016

The American Cancer Society (ACS) has endorsed HPV vaccination recommendations from the CDC's Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's updated guideline supports the ACIP recommendation to vaccinate males as well as females at ages 11 to 12 to protect against HPV, which is associated not only with cervical cancers, but also penile, anal, oropharyngeal (mouth/throat), and other cancers.

The ACS first published a guideline for the use of prophylactic HPV vaccines for the prevention of cervical cancer and pre-cancer in 2007. At the time, the vaccine was not approved for use in males and there was insufficient evidence for vaccinations beyond the age of 18.

Since then, additional studies have added to the evidence, new versions of the vaccine have been licensed for use in the United States, and there have been new immunization recommendations from ACIP.

Studies indicate that vaccination in males will be effective against cancers related to HPV in males, as it is in females. Those cancers include penile cancer in males, cervical, vaginal, and vulvar cancer in females, and anal and oropharyngeal cancers in males and females. Vaccinating males may also provide additional protection to females.

To update its recommendations, the ACS implemented a guideline endorsement process, similar to the approach taken by the American Society of Clinical Oncology (ASCO) for endorsing another organization's guidelines. The adapted ACS endorsement process for the HPV update included a methodologic assessment of the ACIP recommendations, a supplemental evidence review, a content review of the ACIP recommendations, approval of recommendations and endorsement statements by the ACS Guideline Development Group, review of the evidence report and endorsement manuscript by expert advisors, and finally approval of by the ACS National Board of Directors.

A summary of the recommendations:

  • Routine HPV vaccination of all children should be initiated at age 11 or 12. The vaccination series can be started beginning as early as age 9.
  • Vaccination is also recommended for females ages 13 to 26 and for males aged 13 to 21 who have not been vaccinated previously or who have not completed the 3-dose series. Males 22 through 26 years old may also be vaccinated.
    • o The guideline emphasizes that late vaccination for adolescents who were not vaccinated at the recommended age should be completed as soon as possible.

    o Individuals ages 22 to 26 who were not previously vaccinated should be informed that vaccination at older ages is less effective in lowering cancer risk, which is not specifically recommended by the ACIP.

Vaccination of females is recommended with any of the three available vaccines: 2vHPV, 4vHPV (as long as this formulation is available), or 9vHPV. Vaccination of is recommended with 4vHPV (as long as this formulation is available) or 9vHPV. Vaccination is also recommended through age 26 for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously.

"HPV vaccination has the potential to prevent tens of thousands of cancers and hundreds of thousands of pre-cancers each year," said Debbie Saslow, PhD, director of cancer control intervention for HPV vaccination and women's cancers, and lead author of the report. "It is critical that all stakeholders—families, health care providers, and others—make HPV vaccination a priority, so that prevention of the vast majority of cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers can become a reality."

The report appears early online in CA: A Cancer Journal for Clinicians.

Explore further: CDC: Majority of HPV-linked cancers are preventable

More information: Human Papillomavirus Vaccination Guideline Update: American Cancer Society Guideline Endorsement. CA: Can J Clin. DOI: 10.3322/caac.21355

Related Stories

CDC: Majority of HPV-linked cancers are preventable

July 11, 2016
(HealthDay)—The majority of cancers linked to human papillomavirus (HPV) are preventable, according to a report published in the July 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality ...

Expand HPV vaccination programs in Canada to include males

April 25, 2016
Expanding human papillomavirus (HPV) vaccination programs to include males in Canada will help protect them against HPV-related cancers, according to an analysis published in CMAJ (Canadian Medical Association Journal).

ACIP approves 2016 adult immunization schedule

February 4, 2016
(HealthDay)—The Advisory Committee on Immunization Practices (ACIP) has approved the recommended adult immunization schedule for 2016. The recommendations are published as a clinical guideline in the Feb. 2 issue of the ...

ASCO presents guidelines for increasing HPV vaccine uptake

April 12, 2016
(HealthDay)—Recommendations have been developed to increase human papillomavirus (HPV) vaccine uptake, according to an American Society for Clinical Oncology (ASCO) special article published online April 11 in the Journal ...

HPV vaccination expected to reduce cancer in all races, may not eliminate all disparities

April 28, 2016
Human papillomavirus (HPV)-associated cancers occur more frequently, and sometimes with more deadly consequences, among Hispanics, blacks, and American Indian and Alaska Natives than among whites. A new study from Harvard ...

President's panel calls for more girls, boys to get HPV vaccine

February 10, 2014
(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.